Concepedia

John Kemp

JK

16

Publications

765

Citations

14

H-Index

1979

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

John Kemp is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1979–2011

16

Publications

16

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

David McKillop, E. A. Partridge, John Kemp et al. · Molecular Cancer Therapeutics · 2005 · 125 citations

The metabolism of tamoxifen in humans

Hugh K. Adam, Elaine Douglas, John Kemp · Biochemical Pharmacology · 1979 · 91 citations

, , +8

Identification and biological activity of tamoxifen metabolites in human serum

John Kemp, Hugh K. Adam, Alan E. Wakeling et al. · Biochemical Pharmacology · 1983 · 85 citations

, , +8

Excretion of doxepin and N‐desmethyldoxepin in human milk.

John Kemp, KF Ilett, J. Booth et al. · British Journal of Clinical Pharmacology · 1985 · 81 citations · Full text

Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

Hugh K. Adam, John Patterson, John Kemp · PubMed · 1981 · 71 citations

, , +13

Rows per page

1–5 of 16